The world of drug delivery is entering a new phase, and Orexo AB (publ.) (Nasdaq Stockholm: ORX, OTCQX: ORXOY) is helping lead the charge with its AmorphOX® powder technology. The Swedish company, already known for its focus on advancing treatments for opioid use disorder, has just released preclinical data showing that semaglutide, a molecule famous for its use in diabetes and weight management, can be delivered intranasally using this proprietary technique.
Instead of going the usual route with tablets or injections, Orexo’s researchers have formulated three powder-based semaglutide options for delivery through the nose. In a recent in-vivo study, investigators compared these powders directly to oral Rybelsus® and injectable Wegovy®, both well-known semaglutide brands. The results? Two of the three intranasal formulations produced plasma concentrations seven times higher than the oral tablet. These intranasal versions did not reach the plasma levels of injectable Wegovy®, but they did slash the variability in plasma concentrations typically seen with oral dosing.
This is a significant advance on several fronts. First, AmorphOX shows that it can successfully turn large, sensitive molecules like semaglutide into stable powders with high mucosal absorption. Orexo believes this opens new doors for patient-friendly, needle-free administration. An intranasal formulation would not need refrigeration, which means easier storage and transport. For people who are hesitant about needles, or who struggle to remember daily tablets, this type of product could make a noticeable difference in sticking to a long-term care plan.
Robert Rönn, who leads research and development at Orexo, described the breakthrough as an encouraging signal that AmorphOX is not limited to only small molecules, but can tackle bigger challenges like peptides, proteins, and even vaccines. He said these results “underpin our updated AmorphOX strategy,” highlighting a shift to prioritize more complex therapies that could gain from a non-injectable, user-friendly option.
For the pharmaceutical industry, Orexo’s findings are likely to resonate with companies searching for ways to improve treatment adherence, minimize dosing frequency, and boost convenience. In the study, researchers observed that dosing intervals for intranasal semaglutide could be stretched, contingent on the dose strength, possibly making the routine far less burdensome for patients compared to daily tablets. With GLP-1 medications booming in demand for both diabetes and weight management, new approaches like this could bring much-needed alternatives into the hands of healthcare providers.
Founded in Sweden, Orexo draws on three decades of experience refining specialty pharmaceutical delivery. Last year, the company brought in total net sales of $62.6 million (SEK 590 million) and maintained a team of 110 employees. While its core presence is in solutions for opioid dependence in the United States, Orexo also collaborates globally to push innovation into other therapeutic fields.
The AmorphOX news is not just another technical update. It points to a future where large-molecule drugs might be taken without the complexity and limitations of tablets or syringes. As pharmaceutical delivery technology continues to evolve, Orexo is making it clear that intranasal powders could soon become a practical reality, offering new solutions for patients who need flexible, convenient, and effective care.
